Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

IVERIC bio Q3 EPS $(0.23) Beats $(0.29) Estimate

IVERIC bio (NASDAQ:ISEE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 14.81 percent increase over losses of $(0.27) per share from the
byBenzinga Newsdesk
November 9, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

IVERIC bio (NASDAQ:ISEE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 14.81 percent increase over losses of $(0.27) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Protagonist Therapeutics Presented Updated Phase 2 Rusfertide Data in Polycythemia Vera at ASH 2021; Said New Phase 2 Study of Rusfertide in PV Patients With High Hematocrit Levels Demonstrated Rapid Hematocrit Control Without Need for Therapeutic Phle…

By Charles Gross
Today, 4:44 AM
Protagonist Therapeutics (NASDAQ: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating rusfertide in patients with polycythemia vera (PV), demonstrating its ability to essentially eliminate the need for phlebotomies in patients.

PTGX